ClinicalTrials.gov
public full text
Public Domain
A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
This is a phase II/III multicenter, randomized, double-blind, placebo-controlled study, to investigate the efficacy and safety of BAT4406F injection in patients with neuromyelitis optica lineage disease (NMOSD) who are positive for aquaporin 4 antibody (AQP4-IgG) .
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)#913265
- Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.#1045656
- Clinic Registry Study of Optic Neuromyelitis Spectrum Disease in China#801569
- Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders#828590
- MS and NMOSD in African-Americans#843614
Record · ID 901921
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive